Introduction: Increasing family authorization for donation is critical to address the shortage of organs for transplantation, yet there is no standardized method for leading conversations with families about donation.
Objective: The aim of this rapid scoping review is to identify research assessing the components of dual advocacy, a model to discuss organ donation with grieving families.
Methods: PubMed, Web of Science, and grey literature were searched for studies published from 2012 to the present. Data representing the various dual advocacy components that were empirically tested were extracted. Outcomes of interest were authorization for organ donation or family satisfaction with the donation conversation.
Results: Twenty-two articles were identified that tested at least one component of dual advocacy. The most commonly tested component was effective communication about donation ( = 9), including explaining brain death and the donation process. The primary outcome for the majority of studies was donation authorization or conversion rates. Studies that tested all components of dual advocacy ( = 9) had overall positive results while studies that tested a single component had mixed results.
Discussion: Although family authorization to donation is critical to addressing the national organ shortage, there has yet to be a standardized method for leading families in the organ donation conversation. Despite the need for organ transplantation in the United States and worldwide, few large-scale studies have rigorously tested the most effective ways to engage families of donor-eligible patients about the organ donation opportunity. There is an urgent need for further research to establish a standard of evidence-based practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/15269248231189866 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Public health perspectives on green efficiency through smart cities, artificial intelligence for healthcare and low carbon building materials.
Front Public Health
January 2025
School of Fine Art and Design, Guangzhou University, Guangzhou, China.
Introduction: Smart cities, artificial intelligence (AI) in healthcare, and low-carbon building materials are pivotal to public health, environmental sustainability, and green efficiency. Despite their critical importance, understanding public perceptions and attitudes toward these domains remains underexplored. Additionally, the effective use of advanced technologies like convolutional neural networks (CNN) in predicting and promoting low-carbon solutions in construction is gaining attention.
View Article and Find Full Text PDFDurvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.
EClinicalMedicine
January 2025
Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
Background: Dual inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) has been shown to be an effective treatment strategy in many cancers. We sought to determine the objective response rate of combination durvalumab (D) plus tremelimumab (TM) in parallel cohorts of patients with carefully selected rare cancer types in which these agents had not previously been evaluated in phase II trials and for which there was clinical or biological rationale for dual immune checkpoint inhibitor therapy to be active.
Methods: We designed a multi-centre, non-blinded, open-label phase II basket trial with each of the following 8 rare cancers considered a separate phase II trial: salivary carcinoma, carcinoma of unknown primary (CUP) with tumour infiltrating lymphocytes and/or expressing PD-L1, mucosal melanoma, acral melanoma, osteosarcoma, undifferentiated pleomorphic sarcoma, clear cell carcinoma of the ovary (CCCO) or squamous cell carcinoma of the anal canal (SCCA).
Conscientious objection: a global health perspective.
BMJ Glob Health
December 2024
Global Bioethics Collaborative, Los Angeles, California, USA.
Conscientious objection is a critical topic that has been sparsely discussed from a global health perspective, despite its special relevance to our inherently diverse field. In this Analysis paper, we argue that blanket prohibitions of a specific type of non-discriminatory conscientious objection are unjustified in the global health context. We begin both by introducing a nuanced account of conscience that is grounded in moral psychology and by providing an overview of discriminatory and non-discriminatory forms of objection.
View Article and Find Full Text PDFIrisin Improves Preeclampsia by Promoting Embryo Implantation and Vascular Remodeling.
Hypertension
November 2024
West China Second University Hospital, Chengdu, China (X.L.).
Article Synopsis
- - Preeclampsia is a pregnancy-related condition with unclear causes, and the protein irisin, linked to exercise, may play a role in its development and the health of the placenta.
- - Research shows that pregnant individuals with preeclampsia have lower irisin levels, which appear early and correlate with other health indicators like blood pressure and protein levels.
- - Increasing irisin levels in lab studies improved certain functions of trophoblast cells (which support embryo development), while lower levels led to symptoms similar to preeclampsia in animal models.
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
J Thorac Oncol
November 2024
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangzhou, People's Republic of China. Electronic address:
Introduction: PEARL (NCT03003962) is an open-label, phase 3 study comparing first-line durvalumab monotherapy with chemotherapy in patients with metastatic NSCLC (mNSCLC [EGFR/ALK wild type]) with programmed cell death ligand 1 (PD-L1) tumor cell (TC) membrane expression status of 25% or higher. We report the final analysis of PEARL.
Methods: Adults (N = 669) with previously untreated stage IV mNSCLC were randomized (1:1) to durvalumab 20 mg/kg every four weeks or chemotherapy every three weeks for four to six cycles.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!